- Home
- RSSS vs ZNTL Comparison
RSSS vs ZNTL Comparison
Compare RSSS & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSSS
- ZNTL
- Stock Information
- Founded
- RSSS 2006
- ZNTL 2014
- Country
- RSSS United States
- ZNTL United States
- Employees
- RSSS N/A
- ZNTL N/A
- Industry
- RSSS Business Services
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- RSSS Consumer Discretionary
- ZNTL Health Care
- Exchange
- RSSS Nasdaq
- ZNTL Nasdaq
- Market Cap
- RSSS 90.6M
- ZNTL 105.8M
- IPO Year
- RSSS N/A
- ZNTL 2020
- Fundamental
- Price
- RSSS $2.95
- ZNTL $1.33
- Analyst Decision
- RSSS
- ZNTL Buy
- Analyst Count
- RSSS 0
- ZNTL 7
- Target Price
- RSSS N/A
- ZNTL $8.60
- AVG Volume (30 Days)
- RSSS 44.9K
- ZNTL 1.4M
- Earning Date
- RSSS 05-08-2025
- ZNTL 08-08-2025
- Dividend Yield
- RSSS N/A
- ZNTL N/A
- EPS Growth
- RSSS N/A
- ZNTL N/A
- EPS
- RSSS N/A
- ZNTL N/A
- Revenue
- RSSS $48,753,578.00
- ZNTL $26,865,000.00
- Revenue This Year
- RSSS $12.42
- ZNTL N/A
- Revenue Next Year
- RSSS $7.47
- ZNTL N/A
- P/E Ratio
- RSSS N/A
- ZNTL N/A
- Revenue Growth
- RSSS 14.85
- ZNTL N/A
- 52 Week Low
- RSSS $2.32
- ZNTL $1.01
- 52 Week High
- RSSS $4.24
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- RSSS 54.66
- ZNTL 50.91
- Support Level
- RSSS $2.94
- ZNTL $1.15
- Resistance Level
- RSSS $3.10
- ZNTL $1.38
- Average True Range (ATR)
- RSSS 0.09
- ZNTL 0.10
- MACD
- RSSS 0.02
- ZNTL 0.01
- Stochastic Oscillator
- RSSS 62.45
- ZNTL 75.00
About RSSS Research Solutions Inc
Research Solutions Inc is a holding company. The company provides a cloud-based SaaS research intelligence platform consisting of proprietary software and Internet-based interfaces. Its platform also allows customers to find and download digital versions of STM articles. Platforms and Transactions are packaged as a single solution that enables life science and other research-intensive organizations to speed up research and development activities. The company platform allows customers to initiate orders, manage transactions, automate authentication, obtain reports, and connect seamlessly to corporate intranets.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.